Page 81 - GALENIKA MEDICAL JOURNAL

Literatura 21. Yang F, Hellyer JA, Than C, Ullal AJ, Kaiser DW, Heidenreich PA, et al.
Warfarin utilisation and anticoagulation control in patients with atrial
fibrillation and chronic kidney disease. Heart. 2017;103(11):818-26.
1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist 22. Harel Z, Chertow GM, Shah PS, Harel S, Dorian P, Yan AT, et al. Warfarin
C, et al. 2020 ESC Guidelines for the diagnosis and management and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation
of atrial fibrillation developed in collaboration with the European Receiving Dialysis: A Systematic Review and Meta-analysis. Can J
Association for Cardio-Thoracic Surgery (EACTS): The Task Force for Cardiol. 2017;33(6):737-46.
the diagnosis and management of atrial fibrillation of the European
Society of Cardiology (ESC) Developed with the special contribution of 23. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk
the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. stratification for predicting stroke and thromboembolism in atrial
2021;42(5):373-498. fibrillation using a novel risk factor-based approach: the euro heart
survey on atrial fibrillation. Chest. 2010;137(2):263-72.
2. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and
Management: A Review. JAMA. 2019;322(13):1294-304. 24. Van Der Meersch H, De Bacquer D, De Vriese AS. Vitamin K antagonists
3. Winkelmayer WC, Patrick AR, Liu J, Brookhart MA, Setoguchi S. The for stroke prevention in hemodialysis patients with atrial fibrillation: A
systematic review and meta-analysis. Am Heart J. 2017;184:37-46.
increasing prevalence of atrial fibrillation among hemodialysis patients.
J Am Soc Nephrol. 2011;22(2):349-57. 25. Mavrakanas TA, Garlo K, Charytan DM. Apixaban versus No
4. Matusik PT, Heleniak Z, Undas A. Anticoagulant Treatment in Patients Anticoagulation in Patients Undergoing Long-Term Dialysis with
Incident Atrial Fibrillation. Clin J Am Soc Nephrol. 2020;15(8):1146-54.
with Atrial Fibrillation and Chronic Kidney Disease: Practical Issues.
Anatol J Cardiol. 2022;26(12):857-63. 26. Fanola CL, Mooney D, Cowan AJ, Ko D, Sisson EK, Henault LE, et al.
Incidence of severe renal dysfunction among individuals taking
5. Magnocavallo M, Bellasi A, Mariani MV, Fusaro M, Ravera M, Paoletti E, warfarin and implications for non-vitamin K oral anticoagulants. Am
et al. Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients Heart J. 2017;184:150-5.
with Chronic Kidney Disease: Role of Anticoagulation Therapy. J Clin
Med. 2020;10(1). 27. Aursulesei V, Costache II. Anticoagulation in chronic kidney disease:
6. Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase from guidelines to clinical practice. Clin Cardiol. 2019;42(8):774-82.
CM. Systematic review and meta-analysis of incidence, prevalence 28. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns
and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial H, et al. 2024 ESC Guidelines for the management of atrial fibrillation
Transplant. 2012;27(10):3816-22. developed in collaboration with the European Association for Cardio-
7. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, et Thoracic Surgery (EACTS). Eur Heart J. 2024.
al. Atrial fibrillation in hemodialysis patients: clinical features and 29. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et
associations with anticoagulant therapy. Kidney Int. 2010;77(12):1098- al. The 2018 European Heart Rhythm Association Practical Guide on the
106. use of non-vitamin K antagonist oral anticoagulants in patients with
atrial fibrillation. Eur Heart J. 2018;39(16):1330-93.
8. Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et
al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and 30. Simic J, Mihajlovic M, Zec N, Kovacevic V, Marinkovic M, Mujovic N, et al.
Expert Panel Report. Chest. 2018;154(5):1121-201. The impact of anticoagulation therapy on kidney function in patients
9. Bohm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly with atrial fibrillation and chronic kidney disease. Expert Rev Cardiovasc
Ther. 2023;21(12):937-45.
PA, et al. Changes in Renal Function in Patients With Atrial Fibrillation:
An Analysis From the RE-LY Trial. J Am Coll Cardiol. 2015;65(23):2481-93. 31. Brodsky SV, Nadasdy T, Rovin BH, Satoskar AA, Nadasdy GM, Wu HM,
10. Chan KE, Giugliano RP, Patel MR, Abramson S, Jardine M, Zhao S, et et al. Warfarin-related nephropathy occurs in patients with and without
chronic kidney disease and is associated with an increased mortality
al. Nonvitamin K Anticoagulant Agents in Patients With Advanced rate. Kidney Int. 2011;80(2):181-9.
Chronic Kidney Disease or on Dialysis With AF. J Am Coll Cardiol.
2016;67(24):2888-99. 32. Tantisattamo E, Han KH, O'Neill WC. Increased vascular calcification
in patients receiving warfarin. Arterioscler Thromb Vasc Biol.
11. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. 2015;35(1):237-42.
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J
Med. 2011;365(10):883-91. 33. Westenfeld R, Krueger T, Schlieper G, Cranenburg EC, Magdeleyns EJ,
12. Wetmore JB, Ellerbeck EF, Mahnken JD, Phadnis M, Rigler SK, Heidenreich S, et al. Effect of vitamin K2 supplementation on functional
vitamin K deficiency in hemodialysis patients: a randomized trial. Am J
Mukhopadhyay P, et al. Atrial fibrillation and risk of stroke in dialysis Kidney Dis. 2012;59(2):186-95.
patients. Ann Epidemiol. 2013;23(3):112-8.
34. Nigwekar SU, Bloch DB, Nazarian RM, Vermeer C, Booth SL, Xu D, et al.
13. Seliger SL, Gillen DL, Longstreth WT Jr, Kestenbaum B, Stehman-Breen Vitamin K-Dependent Carboxylation of Matrix Gla Protein Influences
CO. Elevated risk of stroke among patients with end-stage renal the Risk of Calciphylaxis. J Am Soc Nephrol. 2017;28(6):1717-22.
disease. Kidney Int. 2003;64(2):603-9.
35. Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, et al.
14. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, et al. Stroke Dialysis accelerates medial vascular calcification in part by triggering
and bleeding in atrial fibrillation with chronic kidney disease. N Engl J smooth muscle cell apoptosis. Circulation. 2008;118(17):1748-57.
Med. 2012;367(7):625-35.
36. Galloway PA, El-Damanawi R, Bardsley V, Pritchard NR, Fry AC, Ojha SK,
15. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, et al. Vitamin K antagonists predispose to calciphylaxis in patients with
et al. Impact of proteinuria and glomerular filtration rate on risk of end-stage renal disease. Nephron. 2015;129(3):197-201.
thromboembolism in atrial fibrillation: the anticoagulation and risk
factors in atrial fibrillation (ATRIA) study. Circulation. 2009;119(10):1363- 37. Han KH, O'Neill WC. Increased Peripheral Arterial Calcification in
9. Patients Receiving Warfarin. J Am Heart Assoc. 2016;5(1).
16. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates 38. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention,
with increased risk for stroke in hemodialysis patients with atrial diagnosis, and treatment. Semin Dial. 2002;15(3):172-86.
fibrillation. J Am Soc Nephrol. 2009;20(10):2223-33.
39. Phelan PJ, O'Kelly P, Holian J, Walshe JJ, Delany C, Slaby J, et al.
17. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and Warfarin use in hemodialysis patients: what is the risk? Clin Nephrol.
safety of warfarin initiation in older hemodialysis patients with incident 2011;75(3):204-11.
atrial fibrillation. Clin J Am Soc Nephrol. 2011;6(11):2662-8.
40. Albrecht D, Turakhia MP, Ries D, Marbury T, Smith W, Dillon D, et al.
18. Sood MM, Larkina M, Thumma JR, Tentori F, Gillespie BW, Fukuhara S, Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe
et al. Major bleeding events and risk stratification of antithrombotic Chronic Kidney Disease. Thromb Haemost. 2017;117(11):2026-33.
agents in hemodialysis: results from the DOPPS. Kidney Int.
2013;84(3):600-8. 41. Limdi NA, Limdi MA, Cavallari L, Anderson AM, Crowley MR, Baird MF,
et al. Warfarin dosing in patients with impaired kidney function. Am J
19. Lai HM, Aronow WS, Kalen P, Adapa S, Patel K, Goel A, et al. Incidence Kidney Dis. 2010;56(5):823-31.
of thromboembolic stroke and of major bleeding in patients with
atrial fibrillation and chronic kidney disease treated with and without 42. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, et
warfarin. Int J Nephrol Renovasc Dis. 2009;2:33-7. al. Net clinical benefit of antithrombotic therapy in patients with atrial
fibrillation and chronic kidney disease: a nationwide observational
20. Kai B, Bogorad Y, Nguyen LN, Yang SJ, Chen W, Spencer HT, et cohort study. J Am Coll Cardiol. 2014;64(23):2471-82.
al. Warfarin use and the risk of mortality, stroke, and bleeding
in hemodialysis patients with atrial fibrillation. Heart Rhythm.
2017;14(5):645-51.
REVIJALNI RADOVI Galenika Medical Journal, 2024; 3(12):73-80. 79